Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan for Helicobacter pylori Eradication: A Randomized, Double-Blind, Active-Controlled Pilot Study

医学 幽门螺杆菌 双盲 随机对照试验 钾 内科学 胃肠病学 替代医学 病理 化学 有机化学 安慰剂
作者
Jae Yong Park,Il Ju Choi,Gwang Ha Kim,Su Jin Hong,Sung Kwan Shin,Seong Woo Jeon,Jae Gyu Kim
出处
期刊:Gut and Liver [Korean Association for the Study of the Liver]
标识
DOI:10.5009/gnl250067
摘要

Triple therapy with vonoprazan, a potassium-competitive acid blocker, has shown an acceptable eradication rate. The aim of this study was to evaluate the efficacy and safety of tegoprazan-based triple therapy compared with those of vonoprazan-based triple therapy for Helicobacter pylori eradication. This randomized, double-blind, active-controlled, multicenter pilot study included treatment-naive adults with H. pylori infection. Participants were randomized 1:1:1 to receive tegoprazan 50 mg (TAC 1), tegoprazan 100 mg (TAC 2), or vonoprazan 20 mg (VAC) with amoxicillin 1,000 mg plus clarithromycin 500 mg twice daily for 10 days. The primary outcome was the eradication rate. Of the 102 enrolled participants, 97 completed the study. The eradication rates in the full analysis set were 60.61% (95% confidence interval [CI], 43.93% to 77.28%), 78.79% (95% CI, 64.84% to 92.74%), and 84.85% (95% CI, 72.62% to 97.08%) in TAC 1, TAC 2, and VAC, respectively. The eradication rates in the per-protocol set were 66.67% (95% CI, 49.80% to 83.54%), 86.67% (95% CI, 74.50% to 98.83%), and 87.50% (95% CI, 76.04% to 98.96%) in TAC 1, TAC 2, and VAC, respectively. In the full analysis set, the eradication rate differences were -6.06% (95% CI, -24.61% to 12.49%) between TAC 2 and VAC and -24.24% (95% CI, -44.92% to -3.56%) between TAC 1 and VAC. In the per-protocol set, the eradication rate differences were -0.83% (95% CI, -19.97% to 17.37%) between TAC 2 and VAC and -20.83% (95% CI, -41.23% to -0.44%) between TAC 1 and VAC. All therapies were well tolerated with no notable safety differences. After 10 days, tegoprazan 100 mg showed eradication rates comparable to those of vonoprazan 20 mg, while 50 mg may be insufficient. These findings support future research to optimize tegoprazan dosing in clinical practice (ClinicalTrials.gov; NCT04128917).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tang发布了新的文献求助10
刚刚
曾经焦焦发布了新的文献求助10
1秒前
令或文发布了新的文献求助10
1秒前
2秒前
知晏发布了新的文献求助10
2秒前
嘤嘤怪完成签到,获得积分10
2秒前
李林泽发布了新的文献求助10
2秒前
3秒前
鳗鱼醉柳完成签到 ,获得积分10
3秒前
wang发布了新的文献求助10
3秒前
Una发布了新的文献求助10
3秒前
二二的叶之梦完成签到,获得积分10
3秒前
ding的应助被曹雪采纳,获得10
4秒前
下雨天发布了新的文献求助10
4秒前
清清清完成签到 ,获得积分10
4秒前
DW的应助被xingxing采纳,获得10
4秒前
www333ccc发布了新的文献求助10
5秒前
5秒前
ding的应助被Lv采纳,获得10
5秒前
摸鱼帝王完成签到,获得积分10
5秒前
青叶摩卡完成签到,获得积分20
5秒前
山东科技李完成签到,获得积分10
6秒前
6秒前
CodeCraft的应助被小巧紫蓝采纳,获得10
6秒前
什么也难不倒我完成签到 ,获得积分10
6秒前
xjx完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
7秒前
Ming完成签到,获得积分10
7秒前
elephant完成签到 ,获得积分10
7秒前
ding的应助被Dimple采纳,获得10
7秒前
syvshc的应助被张正阳采纳,获得10
8秒前
思源的应助被Dongshuxiang123采纳,获得10
8秒前
8秒前
自然的振家完成签到,获得积分10
8秒前
坚定寻冬完成签到,获得积分20
9秒前
9秒前
雪意完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175853
求助须知:如何正确求助?哪些是违规求助? 9567457
关于积分的说明 21792632
捐赠科研通 7770447
什么是DOI,文献DOI怎么找? 3431918
关于科研通互助平台的介绍 2556276
邀请新用户注册赠送积分活动 2477418